100 related articles for article (PubMed ID: 11084461)
21. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma.
Scholten AN; Smit VT; Beerman H; van Putten WL; Creutzberg CL
Cancer; 2004 Feb; 100(4):764-72. PubMed ID: 14770433
[TBL] [Abstract][Full Text] [Related]
22. Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group.
Yamamoto S; Kasajima A; Takano M; Yaegashi N; Fujiwara H; Kuzuya K; Kigawa J; Tsuda H; Kurachi H; Kikuchi Y; Sugiyama T; Tsuda H; Moriya T
Int J Gynecol Pathol; 2011 Mar; 30(2):129-38. PubMed ID: 21293288
[TBL] [Abstract][Full Text] [Related]
23. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
24. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma.
Skírnisdóttir I; Sorbe B
Int J Oncol; 2007 Mar; 30(3):727-34. PubMed ID: 17273775
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in stage I ovarian carcinoma.
Vergote I
Verh K Acad Geneeskd Belg; 2001; 63(3):257-71; discussion 272-6. PubMed ID: 11499346
[TBL] [Abstract][Full Text] [Related]
27. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
28. Clinical prognostic factors in malignant parotid gland tumors.
Lima RA; Tavares MR; Dias FL; Kligerman J; Nascimento MF; Barbosa MM; Cernea CR; Soares JR; Santos IC; Salviano S
Otolaryngol Head Neck Surg; 2005 Nov; 133(5):702-8. PubMed ID: 16274796
[TBL] [Abstract][Full Text] [Related]
29. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
[TBL] [Abstract][Full Text] [Related]
30. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
31. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
32. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
[TBL] [Abstract][Full Text] [Related]
33. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer.
Oehler MK; Caffier H
Anticancer Res; 2000; 20(6D):5109-12. PubMed ID: 11326678
[TBL] [Abstract][Full Text] [Related]
34. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome.
Efstathiou E; Dimopoulos MA; Bozas G; Kastritis E; Moulopoulos LA; Rodolakis A; Vlahos G; Gika D; Papadimitriou C; Bamias A
Anticancer Res; 2007; 27(1B):611-7. PubMed ID: 17348450
[TBL] [Abstract][Full Text] [Related]
35. Stage IV ovarian cancer: prognostic factors and survival beyond 5 years.
Scholz HS; Benedicic C; Haas J; Tamussino K; Petru E
Anticancer Res; 2001; 21(5):3729-32. PubMed ID: 11848553
[TBL] [Abstract][Full Text] [Related]
36. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
37. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages.
O'Brien ME; Schofield JB; Tan S; Fryatt I; Fisher C; Wiltshaw E
Gynecol Oncol; 1993 May; 49(2):250-4. PubMed ID: 8504995
[TBL] [Abstract][Full Text] [Related]
38. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
[TBL] [Abstract][Full Text] [Related]
40. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
